[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639843":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":21,"locations":26,"responsibleParty":42,"collaborators":21,"id":44,"slug":21,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":21,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":21,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":21,"overallStatus":63,"whyStopped":21,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},{"fullName":5,"class":6},"Genovn Therapeutics PTE. LTD.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"IL-15 Enhanced Engineered NK Cells","EXPERIMENTAL","Single arm. Patients receive IL-15 enhanced engineered NK cells after lymphodepletion chemotherapy.",[13,14],"Drug: IL-15 enhanced engineered NK cells","Biological: IL-15 Enhanced Engineered NK Cells",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","IL-15 enhanced engineered NK cells","Genetically engineered NK cells expressing IL-15. Administered intravenously. See protocol for dose details.",[9],null,{"type":23,"name":9,"description":24,"armGroupLabels":25,"otherNames":21},"BIOLOGICAL","Genetically engineered NK cells expressing IL-15",[9],[27],{"facility":28,"status":21,"city":29,"state":21,"zip":21,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Xinqiao Hospital","Chongqing","China",{"type":32,"coordinates":33},"Point",[34,35],106.55771,29.56026,{"lat":35,"lon":34},[38],{"name":28,"role":39,"phone":40,"phoneExt":21,"email":41},"CONTACT","+86-23-68763468","jiaqingzhu0801@outlook.com",{"type":43,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100639843",false,"NCT07621471","IL-15 Enhanced NK Cell Therapy for Solid Tumors","A Single-Arm Clinical Study of IL-15 Enhanced Engineered NK Cells for Refractory Relapsed\u002FMetastatic Solid Tumors","Inclusion Criteria:\n\n1. Age 18-70 years;\n2. ECOG 0-1;\n3. histopathologically confirmed metastatic or recurrent solid tumors (breast, liver, lung, etc.);\n4. failed prior standard therapy;\n5. \\>=1 measurable lesion per RECIST 1.1;\n6. adequate bone marrow, liver, kidney, and coagulation function;\n7. recovered from prior treatment toxicities;\n8. signed informed consent.\n\nExclusion Criteria:\n\n1. Pregnancy\u002Flactation;\n2. other malignancy within 5 years (except cured localized tumors);\n3. active autoimmune disease or immunodeficiency;\n4. uncontrolled cardiovascular disease or infection;\n5. active TB;\n6. positive HBsAg\u002FHBcAb or HCV antibody (unless viral load undetectable);\n7. positive syphilis antibody;\n8. major surgery or vaccination within 28 days;\n9. prior cell therapy;\n10. severe allergy to study drugs;\n11. investigator judged unsuitable.","ALL","18 Years","70 Years",{"count":54,"type":55},12,"ESTIMATED","INTERVENTIONAL",[58],"EARLY_PHASE1","A single-arm, Phase 1 study evaluating safety, tolerability, and preliminary efficacy of IL-15 enhanced engineered NK cells in patients with refractory relapsed or metastatic solid tumors.",[61,62],"Solid Tumors","Metastatic Cancer","NOT_YET_RECRUITING","2026-05-27",{"date":66,"type":67},"2026-06-02","ACTUAL",{"date":69,"type":55},"2026-07-01",{"date":71,"type":55},"2028-12-31",{"name":73,"class":6},"Genovn Therapeutics (Suzhou) Co., Ltd.",1]